{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05532722",
            "orgStudyIdInfo": {
                "id": "ABC008-LGL-101"
            },
            "organization": {
                "fullName": "Abcuro, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)",
            "officialTitle": "A Study of ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-subjects-with-t-cell-large-granular-lymphocytic-leukemia-t-lgll"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-09-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-08-19",
            "studyFirstSubmitQcDate": "2022-09-06",
            "studyFirstPostDateStruct": {
                "date": "2022-09-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-14",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Abcuro, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "An open label, ascending dose study for adult subjects with T-cell Large Granular Lymphocytic Leukemia (T-LGLL)"
        },
        "conditionsModule": {
            "conditions": [
                "T-cell Large Granular Lymphocytic Leukemia"
            ],
            "keywords": [
                "T-cell Large Granular Lymphocytic Leukemia",
                "T-LGLL"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ABC008 Dose Level 1 Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "0.25 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.\n\nCohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.",
                    "interventionNames": [
                        "Drug: ABC008"
                    ]
                },
                {
                    "label": "ABC008 Dose Level 2 Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "0.75 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.\n\nCohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.",
                    "interventionNames": [
                        "Drug: ABC008"
                    ]
                },
                {
                    "label": "ABC008 Dose Level 3 Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "1.5 mg / kg ABC008 Subjects receive ABC008 every 8 weeks.\n\nCohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.",
                    "interventionNames": [
                        "Drug: ABC008"
                    ]
                },
                {
                    "label": "ABC008 Dose Level 4 Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "3.0 mg / kg ABC008 Subjects receive ABC008 every 8 weeks OR 1.5 mg / kg Subjects receive ABC008 every 4 weeks.\n\nCohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.",
                    "interventionNames": [
                        "Drug: ABC008"
                    ]
                },
                {
                    "label": "ABC008 Dose Level 5 Cohort",
                    "type": "EXPERIMENTAL",
                    "description": "3.0 mg / kg ABC008 Subjects receive ABC008 every 4 weeks.\n\nCohorts receive escalating doses of ABC008 until completion of cohort 5 or any cohort is determined to have exceeded the maximum tolerated dose.",
                    "interventionNames": [
                        "Drug: ABC008"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ABC008",
                    "description": "Given subcutaneous injection",
                    "armGroupLabels": [
                        "ABC008 Dose Level 1 Cohort",
                        "ABC008 Dose Level 2 Cohort",
                        "ABC008 Dose Level 3 Cohort",
                        "ABC008 Dose Level 4 Cohort",
                        "ABC008 Dose Level 5 Cohort"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence, nature, and severity of treatment-emergent AEs and SAEs as determined by NCI CTCAE v5.0",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change from baseline in safety lab (Hematology)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in safety lab (Chemistry)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in safety lab (Coagulation)",
                    "description": "Includes the following coagulation labs: INR and aPTT",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in safety lab (Complement)",
                    "description": "Includes the following complement labs: C3 and CH50",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in safety lab (Cytokines)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in safety lab (CMV Viral Load)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in safety lab (EBV Viral Load)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in ECG (Rhythm)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in ECG (Heart Rate)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in ECG parameters",
                    "description": "Includes the following ECG parameters: RR interval, PR interval, QRS interval, QT interval, QT interval corrected by Bazett's formula, and QTcF",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in vital sign (Systolic and diastolic blood pressure)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in vital sign (temperature)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in vital sign (respiratory rate)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Change from baseline in vital sign (pulse rate)",
                    "timeFrame": "Through Study Completion an average of 48 weeks"
                },
                {
                    "measure": "Percentage of subjects demonstrating overall response (defined as total number of subjects with CR or PR) at all time points assessed",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "Percentage of subjects demonstrating complete response at all time points assessed",
                    "description": "A complete response is defined by normalization of hemoglobin, neutrophil and platelet levels without transfusion",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "Percentage of subjects demonstrating partial response at all time points assessed",
                    "description": "A partial response is defined by improvement in any of the following criteria but not all: hemoglobin, neutrophil and platelet levels without transfusion",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "Duration of response at all time points assessed",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "Overall survival at Week 48",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The change from baseline in levels of KLRG1 expressing lymphocytes over time",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The change from baseline in levels of T-LGL counts over time",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The change from baseline in levels of lymphocyte subsets over time",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The maximum serum concentration [CMax] of ABC008",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The time to maximum concentration [TMax] of ABC008",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The area under the concentration-time curve [AUC] of ABC008",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The apparent clearance [CL/F] of ABC008",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The apparent volume of distribution [Vd/F] of ABC008",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                },
                {
                    "measure": "The elimination half-life [t\u00bd] of ABC008",
                    "timeFrame": "Day 1 and throughout the 48 weeks of follow up"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Is at least 18 years of age.\n* Has body mass index (BMI) \u226435 kg/m2.\n* Has a documented diagnosis of T LGLL.\n* Has any 1 or more of the following at Screening:\n\n  * Absolute neutrophil count (ANC) \\<0.5 x 109/L\n  * ANC \u22650.5 x 109/L and \\<1.0 x 109/L associated with recurrent infection (\u22652 or more infections requiring antimicrobial therapy within the previous 12 months)\n  * Hemoglobin (Hgb) \\<8 g/dL or packed red blood cell transfusion frequency \u22651 time in the 4 weeks immediately prior to Screening\n  * Hgb \u22658 g/dL and \\<10 g/dL accompanied by documented symptoms of anemia, e.g., fatigue, weakness, pale or yellowish skin, irregular heartbeat, shortness of breath, dizziness, or lightheadedness.\n* Has adequate hepatic and renal function at Screening, as indicated by:\n\n  * Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST); \\<2.5x the upper limit of normal (ULN)\n  * Total bilirubin \u22641.5 ULN; subjects with Gilbert syndrome must have a total bilirubin \\<3.0x ULN with direct bilirubin \\<1.0x ULN at time of Screening\n  * Estimated glomerular filtration rate (eGFR) \u226545 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) equation corrected for the body surface area of the subject calculated by the Mosteller equation and divided by 1.73\n* Agrees to adhere to the current Centers for Disease Control advice regarding minimizing exposure to severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) from the first Screening Visit until the End of Study (EOS)/Early Termination Visit (ETV).\n\nExclusion Criteria:\n\n* Has reactive large granular lymphocytosis.\n* Has active anemia secondary to confirmed etiologies other than T-LGLL, including known vitamin or mineral deficiency, gastrointestinal bleeding, or genetic disorder; or has active neutropenia secondary to known vitamin or mineral deficiencies or genetic disorder.\n* Has a platelet count \u226420 x 109/L or other clinically significantly abnormal laboratory results not related to the underlying condition in the Investigator's or Sponsor's opinion at Screening.\n* Has known hypersensitivity to any component of the formulation of ABC008, or history of anaphylaxis to any prior mAb therapy.\n* Has any other autoimmune or autoinflammatory disease other than RA, inclusion body myositis (IBM), secondary Sjogren's syndrome (SS), or thyroid disease.\n* Has another myelo /lympho proliferative disorder or malignancy (other than monoclonal gammopathy of unknown significance \\[MGUS\\] not requiring treatment) within the past 5 years prior to Screening except completely resected nonmelanoma skin cancer, curatively treated localized prostate cancer, and completely resected carcinoma in situ at any site.\n* Has a current diagnosis of active tuberculosis (TB)\n* Has a history of herpes zoster infection that was disseminated, required hospitalization, or IV antiviral therapy in the 24 weeks prior to Day 1.\n* Active, chronic, or past history of hepatitis B virus or hepatitis C virus (HCV) infection (hepatitis B core antibody or surface antigen positive, or HCV antibody positive with reflex HCV ribonucleic acid \\[RNA\\] positive at Screening; individuals who have received curative therapy for HCV are permitted if therapy was completed at least 24 weeks prior to Screening and subject is HCV RNA negative);\n* Has known active bacterial, viral, fungal, or atypical mycobacterial infection, or any major episode of infection that required hospitalization\n* Has received live (including attenuated) vaccination in the 30 days prior to Day 1 or killed vaccine within 14 days prior to Day 1.\n* Is human immunodeficiency virus (HIV) positive by antigen/antibody test, human T cell lymphotropic virus (HTLV 1 or 2) positive by antibody test.\n* Has had major surgery (defined as surgery requiring general or regional anesthesia) within 6 weeks prior to Day 1 or is expected to receive surgery during the study.\n* Has a history of organ transplant (e.g., solid, bone marrow) or is expected to receive one during the study.\n* Has any other condition or social situations that would interfere with the subject's study participation, increase the risk associated with study participation or investigational product administration, interfere with the interpretation of study results, or would otherwise make the subject inappropriate for entry into this study in the Investigator's or Sponsor's opinion.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael McClain",
                    "role": "CONTACT",
                    "phone": "617-865-5078",
                    "email": "LGL-101_ClinicalTrial@abcuro.com"
                }
            ],
            "locations": [
                {
                    "facility": "City of Hope",
                    "status": "RECRUITING",
                    "city": "Duarte",
                    "state": "California",
                    "zip": "91010",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Ryotaro Nakamura, M.D.",
                            "role": "CONTACT",
                            "phone": "877-467-3411"
                        },
                        {
                            "name": "Ryotaro Nakamura, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.13945,
                        "lon": -117.97729
                    }
                },
                {
                    "facility": "University of Southern California",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90033",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Christine Duran",
                            "role": "CONTACT",
                            "email": "duran_c@med.usc.edu"
                        },
                        {
                            "name": "Howard Liebman, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "Massachusetts General Hospital",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02114",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Salvia Jain",
                            "role": "CONTACT",
                            "phone": "617-724-4000"
                        },
                        {
                            "name": "Salvia Jain, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Dana-Farber Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Boston",
                    "state": "Massachusetts",
                    "zip": "02215",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "DFCI Clinical Trial Hotline",
                            "role": "CONTACT",
                            "phone": "877-338-7425"
                        },
                        {
                            "name": "Eric Jacobsen, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.35843,
                        "lon": -71.05977
                    }
                },
                {
                    "facility": "Icahn School of Medicine at Mount Sinai",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10029",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Erin Demakos",
                            "role": "CONTACT",
                            "phone": "212-241-5520",
                            "email": "erin.demakos@mssm.edu"
                        },
                        {
                            "name": "Lewis Silverman, M.D.",
                            "role": "CONTACT",
                            "phone": "212 241-5520",
                            "email": "Lewis.Silverman@mssm.edu"
                        },
                        {
                            "name": "Lewis Silverman, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "SUNY Upstate Medical University",
                    "status": "WITHDRAWN",
                    "city": "Syracuse",
                    "state": "New York",
                    "zip": "13210",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 43.04812,
                        "lon": -76.14742
                    }
                },
                {
                    "facility": "Cleveland Clinic Foundation",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Moaath Mustafa Ali, M.D.",
                            "role": "CONTACT",
                            "phone": "866-223-8100",
                            "email": "taussigresearch@ccf.org"
                        },
                        {
                            "name": "Moaath Mustafa Ali, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "The University of Texas M.D. Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Tapan Kadia, M.D.",
                            "role": "CONTACT",
                            "phone": "713-563-3435",
                            "email": "tkadia@mdanderson.org"
                        },
                        {
                            "name": "Tapan Kadia, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute, University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "David L Samuel",
                            "role": "CONTACT",
                            "phone": "801-587-9834",
                            "email": "David.Samuel@hci.utah.edu"
                        },
                        {
                            "name": "Paul J Shami, M.D.",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000054066",
                    "term": "Leukemia, Large Granular Lymphocytic"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000015458",
                    "term": "Leukemia, T-Cell"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "asFound": "Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M27552",
                    "name": "Leukemia, Large Granular Lymphocytic",
                    "asFound": "T-Cell Large Granular Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18119",
                    "name": "Leukemia, T-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "T238",
                    "name": "Aggressive NK Cell Leukemia",
                    "asFound": "Large Granular Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5568",
                    "name": "T-cell Large Granular Lymphocyte Leukemia",
                    "asFound": "T-Cell Large Granular Lymphocytic Leukemia",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}